ImageneBio (IMA) Total Non-Current Liabilities (2023 - 2025)
ImageneBio (IMA) posted Total Non-Current Liabilities of $19.0 million for Q4 2025, down 4.87% sequentially from $19.9 million in Q3 2025, and up 8.71% YoY from $17.4 million in Q4 2024.
ImageneBio (IMA) Total Non-Current Liabilities (2023 - 2025) Analysis & Trends
ImageneBio has reported Total Non-Current Liabilities for 3 years, with the latest figure at $19.0 million in Q4 2025.
- Quarterly Total Non-Current Liabilities rose 8.71% year-over-year to $19.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $19.0 million (up 8.71% YoY) and the FY2025 annual result came in at $19.0 million, up 8.71% from the prior year.
- Total Non-Current Liabilities fell to $19.0 million in Q4 2025 per IMA's latest filing, from $19.9 million in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $21.4 million in Q4 2023 and troughed at $9.2 million in Q2 2025.
- A 3-year average of $15.8 million and a median of $16.5 million in 2024 frame the typical range for Total Non-Current Liabilities.
- The widest YoY moves for Total Non-Current Liabilities: up 45.42% in 2025, down 32.56% in 2025.
- Over 3 years, Total Non-Current Liabilities stood at $21.4 million in 2023, then dropped by 18.41% to $17.4 million in 2024, then climbed by 8.71% to $19.0 million in 2025.
- According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $19.0 million, $19.9 million, and $9.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.20 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.17 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 9.32 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 724.15 Mn |
| 10 | ImageneBio | 48.60 Mn | -86.75 Mn | - | 18.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 18.97 Mn |
| Sep 30, 2025 | 19.94 Mn |
| Jun 30, 2025 | 9.17 Mn |
| Mar 31, 2025 | 11.51 Mn |
| Dec 31, 2024 | 17.45 Mn |
| Sep 30, 2024 | 13.71 Mn |
| Jun 30, 2024 | 13.59 Mn |
| Mar 31, 2024 | 16.47 Mn |
| Dec 31, 2023 | 21.39 Mn |